Generation Bio (GBIO) to Release Earnings on Thursday

Generation Bio (NASDAQ:GBIO) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($2.81) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 16, 2026 at 5:00 PM ET.

Generation Bio Price Performance

Shares of NASDAQ GBIO opened at $5.34 on Tuesday. The stock has a market capitalization of $35.99 million, a P/E ratio of -0.57 and a beta of 2.05. Generation Bio has a one year low of $3.00 and a one year high of $8.20. The firm’s 50 day simple moving average is $5.48 and its two-hundred day simple moving average is $5.65.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Generation Bio to a “sell” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Citigroup restated a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Wedbush set a $5.50 price objective on Generation Bio and gave the company an “outperform” rating in a research note on Tuesday, December 16th. Finally, Jefferies Financial Group downgraded Generation Bio from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $11.00 to $5.00 in a report on Tuesday, December 16th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.88.

Institutional Trading of Generation Bio

Large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Generation Bio by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 51,795 shares of the company’s stock valued at $294,000 after purchasing an additional 1,990 shares in the last quarter. Shay Capital LLC purchased a new position in shares of Generation Bio during the third quarter valued at about $64,000. ADAR1 Capital Management LLC bought a new position in Generation Bio in the third quarter worth about $136,000. Torno Capital LLC bought a new position in Generation Bio in the fourth quarter worth about $142,000. Finally, DRW Securities LLC purchased a new stake in Generation Bio in the fourth quarter worth about $249,000. Institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.